Menu Search
Equities

Jazz Pharmaceuticals PLC

J7Z:FRA

Jazz Pharmaceuticals PLC

Actions
  • Price (EUR)114.75
  • Today's Change-0.45 / -0.39%
  • Shares traded45.00
  • 1 Year change+4.18%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 07:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

  • Revenue in USD (TTM)3.99bn
  • Net income in USD463.16m
  • Incorporated2005
  • Employees2.80k
  • Location
    Jazz Pharmaceuticals PLCFifth FlWaterloo Exchange, Waterloo RoadDUBLIN 4IrelandIRL
  • Phone+353 16347800
  • Fax+353 16347850
  • Websitehttps://www.jazzpharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		JAZZ:NSQ since
announced		Transaction
value
Redx Pharma PLC-KRAS Inhibitor ProgramAnnounced07 Feb 202407 Feb 2024Announced-0.88%--
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.